Impact of Androgen Deprivation Therapy Associated to Conformal Radiotherapy in the Treatment of D'Amico Intermediate-/High-Risk Prostate Cancer in Older Patients.

3D conformal external beam radiotherapy androgen deprivation therapy localized prostate cancer older adults

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
29 Dec 2020
Historique:
received: 19 11 2020
revised: 18 12 2020
accepted: 24 12 2020
entrez: 1 1 2021
pubmed: 2 1 2021
medline: 2 1 2021
Statut: epublish

Résumé

The association of 3D Conformal External Beam Radiotherapy (3D-CEBRT) with adjuvant Androgen Deprivation Therapy (ADT) proved to treat patients with intermediate- and high-risk localized prostate cancer (IR and HR). However, older patients were underrepresented in literature. We aimed to report the oncological results and morbidity 3D-CEBRT +ADT in ≥80 years patients. From June 1998 to July 2017, 101 patients ≥80 years were included in a tertiary center. The median age was 82 years. ADT was initiated 3 months prior 3D-CEBRT in all patients, with a total duration of 6 months for IR prostate cancer (group A; Five years-OS was 95% and 86.7% in groups A and B, respectively. Cardiovascular events occurred in 22.8% of ≥80 years patients with no impact on OS. In the multivariate analysis, age <82 years, Karnofsky index and normalization of testosterone levels were significantly associated with better OS. Age ≥80 years should not be a limitation for the treatment of IR and HR prostate cancer patients with 3D-CEBRT and ADT, but cardiovascular monitoring and prevention are mandatory.

Identifiants

pubmed: 33383957
pii: cancers13010075
doi: 10.3390/cancers13010075
pmc: PMC7795189
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

JAMA. 2011 Dec 7;306(21):2359-66
pubmed: 22147380
Radiother Oncol. 2011 Dec;101(3):460-4
pubmed: 21864924
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
N Engl J Med. 2008 Mar 20;358(12):1250-61
pubmed: 18354103
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Clin Geriatr Med. 2009 Nov;25(4):563-77, vii
pubmed: 19944261
Eur J Cancer. 2019 Jul;116:116-136
pubmed: 31195356
J Clin Endocrinol Metab. 2002 Feb;87(2):589-98
pubmed: 11836290
Lancet. 2009 Jan 24;373(9660):301-8
pubmed: 19091394
BMC Cancer. 2015 Nov 02;15:837
pubmed: 26525985
J Clin Oncol. 2008 Feb 1;26(4):585-91
pubmed: 18172188
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
N Engl J Med. 2005 Jan 13;352(2):154-64
pubmed: 15647578
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90
pubmed: 15817329
Cancer. 1998 Jan 15;82(2):334-41
pubmed: 9445191
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):191-9
pubmed: 21109361
Urology. 2004 Apr;63(4):742-5
pubmed: 15072892
Cancer. 2003 Jan 1;97(1):56-62
pubmed: 12491505
Lancet. 2011 Dec 17;378(9809):2104-11
pubmed: 22056152
J Clin Oncol. 1998 Apr;16(4):1582-7
pubmed: 9552069
Lancet Oncol. 2011 May;12(5):451-9
pubmed: 21440505
J Clin Oncol. 2016 May 20;34(15):1748-56
pubmed: 26976418
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Eur Urol. 2015 Sep;68(3):386-96
pubmed: 25484142
PLoS One. 2018 Apr 9;13(4):e0194173
pubmed: 29630602
Cancer. 2007 Dec 15;110(12):2604-13
pubmed: 17960609
N Engl J Med. 2009 Jun 11;360(24):2516-27
pubmed: 19516032
Lancet Oncol. 2012 Jun;13(6):e259-69
pubmed: 22652234
Lancet Oncol. 2014 Aug;15(9):e404-14
pubmed: 25079103
Lancet. 2017 Apr 1;389(10076):1323-1335
pubmed: 28236464
JAMA. 2008 Jan 23;299(3):289-95
pubmed: 18212313
J Clin Endocrinol Metab. 2011 Oct;96(10):3007-19
pubmed: 21816776
Support Care Cancer. 2013 Jun;21(6):1761-71
pubmed: 23455492
Prog Urol. 2005 Apr;15(2):260-4
pubmed: 15999604
J Clin Oncol. 2011 Jan 10;29(2):235-41
pubmed: 21135285
J Urol. 2006 Dec;176(6 Pt 1):2443-7
pubmed: 17085125
PLoS One. 2014 Sep 29;9(9):e107516
pubmed: 25264674
Cancer. 2004 Jan 1;100(1):72-81
pubmed: 14692026
J Clin Oncol. 2003 May 1;21(9):1653-9
pubmed: 12721238

Auteurs

Anne-Laure Couderc (AL)

Internal Medicine, Geriatric and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), and Coordination Unit for Geriatric Oncology (UCOG), PACA West, 13009 Marseille, France.
Medical School, Aix-Marseille University, 13005 Marseille, France.

Emanuel Nicolas (E)

Department of Medical Oncology, University Hospital of Nimes, 30000 Nimes, France.
IDESP Institute Desbrest of Epidemiology and Public Health, Research Unit INSERM, University of Montpellier, 34000 Montpellier, France.

Romain Boissier (R)

Medical School, Aix-Marseille University, 13005 Marseille, France.
Urology Department, Conception Hospital, AP-HM, 13005 Marseille, France.

Mohammed Boucekine (M)

Department of Public Health, EA 3279 Self-Perceveid Health Assessment Research Unit, Medical School, Aix-Marseille University, 13005 Marseille, France.

Cyrille Bastide (C)

Medical School, Aix-Marseille University, 13005 Marseille, France.
Urology Department, Nord Hospital, AP-HM, 13015 Marseille, France.

Delphine Badinand (D)

Radiotherapy Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Dominique Rossi (D)

Medical School, Aix-Marseille University, 13005 Marseille, France.
Urology Department, Nord Hospital, AP-HM, 13015 Marseille, France.

Benedicte Mugnier (B)

Internal Medicine, Geriatric and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), and Coordination Unit for Geriatric Oncology (UCOG), PACA West, 13009 Marseille, France.

Patrick Villani (P)

Internal Medicine, Geriatric and Therapeutic Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), and Coordination Unit for Geriatric Oncology (UCOG), PACA West, 13009 Marseille, France.
Medical School, Aix-Marseille University, 13005 Marseille, France.

Gilles Karsenty (G)

Medical School, Aix-Marseille University, 13005 Marseille, France.
Urology Department, Conception Hospital, AP-HM, 13005 Marseille, France.

Didier Cowen (D)

Medical School, Aix-Marseille University, 13005 Marseille, France.
Radiotherapy Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Eric Lechevallier (E)

Medical School, Aix-Marseille University, 13005 Marseille, France.
Urology Department, Conception Hospital, AP-HM, 13005 Marseille, France.

Xavier Muracciole (X)

Radiotherapy Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Classifications MeSH